Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study (Q40720626)

From Wikidata

Jump to navigation Jump to search

scientific article published on 19 July 2015

Language	Label	Description	Also known as
English	Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study	scientific article published on 19 July 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

3

object named as

Adam Savitz

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

author name string

Paulien Ravenstijn

1

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Bart Remmerie

2

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Mahesh N Samtani

4

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Isaac Nuamah

5

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Cheng-Tao Chang

6

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Marc De Meulder

7

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

David Hough

8

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Srihari Gopal

9

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

publication date

19 July 2015

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

56

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

330-339

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.597

21 January 2018

A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.597

21 January 2018

Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.597

21 January 2018

Predictors of relapse in the year after hospital discharge among patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.597

21 January 2018

A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.597

21 January 2018

Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.597

21 January 2018

A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.597

21 January 2018

Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.597

21 January 2018

Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.597

21 January 2018

Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.597

21 January 2018

Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.597

21 January 2018

A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.597

21 January 2018

A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.597

21 January 2018

Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.597

21 January 2018

Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.597

21 January 2018

Validated method for the determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography-tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.597

21 January 2018

A rating scale for drug-induced akathisia

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.597

21 January 2018

Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.597

21 January 2018

Identifiers

10.1002/JCPH.597

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40720626&oldid=2144493587"